Italy's Angelini Pharma teams up with JCR on blood-brain barrier deal

Paul Schloesser

Associate Editor

Angelini Pharma plans to pay Japanese pharma JCR Pharmaceuticals more than $500 million as part of a research collaboration that focuses on the blood-brain barrier …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Italy's Angelini Pharma teams up with JCR on blood-brain barrier deal

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Italy's An­geli­ni Phar­ma teams up with JCR on blood-brain bar­ri­er deal

Associate Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Italy's Angelini Pharma teams up with JCR on blood-brain barrier deal